Oncogene targeted therapy for metastatic primary scrotal melanoma.

Journal: The Canadian Journal of Urology
Treatment Used: Oncogene Targeted Therapy, Dabrafenib
Number of Patients: 1
MediFind Summary

Overview: This case report describes a 79-year-old patient diagnosed with metastatic primary scrotal melanoma treated with oncogene targeted therapy, dabrafenib.

Conclusion: This is the first patient with metastatic primary scrotal melanoma who will be treated with oncogene targeted therapy, dabrefenib.

Abstract

Primary scrotal melanoma represents the rarest genitourinary malignancy. We describe the 25th reported case. The 79-year-old patient presented with a rapidly enlarging right cutaneous scrotal mass which after local excision demonstrated pT4b nodular malignant melanoma (BRAF V600E mutation positive). The patient underwent wide local excision of his hemiscrotum and inguinal lymph node dissection demonstrating nodes positive for melanoma (pN2b). Postoperatively, the patient developed a left sided malignant pleural effusion (M1b). Per American Joint Commission Cancer staging, BRAF mutant targeted therapy (dabrafenib) was initiated. This case documents the first instance in which metastatic scrotal melanoma will be treated with oncogene targeted therapy.

Read More
Authors
Blair Stocks, Hunter Fuentes, Zachary Mcdowell, Michael Brooks, Jeffrey Jones

View Article From Source

Similar Latest Advances